Drugs / Ulodesine
Ulodesine
also known as
BCX4208 · BCX-3408 · BCX-4208 HEMISUCCINATE HYDRATE · Dadme-immucillin h · LR-09 · R-3421 · Ulodesina · ULODESINE SUCCINATE
Small molecule targets PNP via inhibition
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01407874 | Sep 2011 → Jul 2012 | arthritic joint disease, gout, impaired renal function disease | BioCryst Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT01265264 | Dec 2010 → Jul 2012 | arthritic joint disease, gout | BioCryst Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT01129648 | May → Nov 2010 | gout | BioCryst Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00985127 | Sep 2009 → Sep 2010 | gout | BioCryst Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 13 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ulodesine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01407874 ↗ |
| Known as | BCX-3408 | ChEMBL registry synonym — accepted as the source's own label CHEMBL269864 ↗ |
| Known as | BCX-4208 HEMISUCCINATE HYDRATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL269864 ↗ |
| Known as | BCX4208 | “Ulodesine (BCX4208) 5 mg” NCT01407874 ↗ |
| Known as | Dadme-immucillin h | ChEMBL registry synonym — accepted as the source's own label CHEMBL269864 ↗ |
| Known as | LR-09 | ChEMBL registry synonym — accepted as the source's own label CHEMBL269864 ↗ |
| Known as | R-3421 | ChEMBL registry synonym — accepted as the source's own label CHEMBL269864 ↗ |
| Known as | Ulodesina | ChEMBL registry synonym — accepted as the source's own label CHEMBL269864 ↗ |
| Known as | ULODESINE SUCCINATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL269864 ↗ |
| Action | Inhibit | “Purine nucleoside phosphorylase inhibitor” CHEMBL269864 ↗ |
| Modality | Small molecule | — CHEMBL269864 ↗ |
| Route | Oral | “Oral dose administered daily for 84 days.” NCT01265264 ↗ |
| Target | PNP | “Purine nucleoside phosphorylase inhibitor” CHEMBL269864 ↗ |